Wells Fargo Cuts PT on MetLife, Inc. (MET) to $93 From $97, Here’s Why

MetLife, Inc. (NYSE:MET) is one of the best cheap blue chip stocks to buy according to analysts. On February 25, Wells Fargo cut the price target on MetLife, Inc. (NYSE:MET) to $93 from $97 while maintaining an Overweight rating on the shares, telling investors that with guidance from most companies in fiscal Q4, the firm is generally cutting its EPS estimates as guides were in line with or below consensus expectations for most companies. It also stated that it is rolling valuation methodologies to 2027 EPS and rolling out new 2028E EPS estimates for companies.

Is MetLife Inc. (MET) the Best Health Insurance Stock to Buy in 2025?

MetLife, Inc. (NYSE:MET) also received a rating update from Mizuho on February 12, with the firm cutting the price target on the stock to $100 from $102 and reaffirming an Outperform rating on the shares. In another development, Evercore ISI adjusted the price target on MetLife, Inc. (NYSE:MET) on February 11. The firm cut the price target on the stock to $95 from $97, keeping an In Line rating on the shares and telling investors that it adjusted estimates after the company released its quarterly report.

MetLife, Inc. (NYSE:MET) provides insurance and financial services to individual and institutional customers. The company’s operations are divided into the following segments: Group Benefits, Retirement and Income Solutions (RIS), Asia, MetLife Holdings, and Corporate and Other.

While we acknowledge the potential of MET to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MET and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.